pradigastat

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
1. Pradigastat is a potent and specific diacylglycerol acyltransferase-1 (DGAT1) inhibitor effective in lowering postprandial… (More)
Is this relevant?
2017
2017
Hepatitis C virus (HCV) infection is a significant cause of liver disease affecting 80-150 million people globally… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2016
2016
Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To… (More)
Is this relevant?
2016
2016
Pradigastat, a novel diacylglycerol acyltransferase-1 inhibitor, has activity in common metabolic diseases associated with… (More)
Is this relevant?
2015
2015
Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency resulting… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Pradigastat is a potent and selective inhibitor of diacylglycerol acyltransferase 1, an enzyme highly expressed in the small… (More)
Is this relevant?
2015
2015
Pradigastat, a diacylglycerol acyltransferase 1 inhibitor, is being developed for the treatment of familial chylomicronemia… (More)
Is this relevant?
2015
2015
BACKGROUND AND OBJECTIVE Pradigastat, a diacylglycerol acyltransferase1 inhibitor, is being developed for the treatment of… (More)
Is this relevant?
2015
2015
BACKGROUND AND OBJECTIVE Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, is under development to treat familial… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
2014
2014
Pradigastat, a novel diacylglycerol acyltransferase-1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic… (More)
Is this relevant?